Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients |
| |
| Affiliation: | 1. Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey;2. Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey;3. Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey;4. Division of Nephrology, Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey;1. Department of Nutrition and Dietetics, School of Health, Tekirdağ Namık Kemal University, Tekirdağ, Turkey;2. Department of Nephrology and Transplantation, School of Medicine, University of Health Sciences, İstanbul, Turkey;3. Department of General Surgery, Faculty of Medicine, Tekirdağ Namık Kemal University, Tekirdağ, Turkey;1. Department of Surgery, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;2. 2nd Department of Medicine and Cardiology Centre, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;3. 1st Department of Medicine, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;4. Department for Medical Translation and Communication, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;1. Department of Cardiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey;2. Department of General Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkey;3. Department of Neurology, Faculty of Medicine, Akdeniz University, Antalya, Turkey;1. Department of Psychiatry, Istanbul Yeniyuzyil University Gaziosmanpasa Hospital, İstanbul, Gaziosmanpasa, Turkey;2. Department of Organ Transplantation, Istanbul Yeniyuzyil University Gaziosmanpasa Hospital, İstanbul, Gaziosmanpasa, Turkey;3. Department of Internal Medicine and Organ Transplantation, Istanbul Yeniyuzyil University Gaziosmanpasa Hospital, İstanbul, Gaziosmanpasa, Turkey;1. Department of Nephrology, University of Health Sciences, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey;2. Department of Internal Medicine, Ege University Medical Faculty, İzmir, Turkey;3. Department of Pathology, Ege University Medical Faculty, İzmir, Turkey;4. Department of Nephrology, Ege University Medical Faculty, İzmir, Turkey;5. Department of Nephrology, Trakya University Medical Faculty, Edirne, Turkey;1. Department of General Surgery, Dokuz Eylul University School of Medicine, Izmir, Turkey;2. Department of Pathology, Dokuz Eylul University School of Medicine, Izmir, Turkey;3. Department of Preventive Oncology, Dokuz Eylul University School of Medicine, Izmir, Turkey |
| |
| Abstract: | IntroductionCardiovascular disease is the leading cause of mortality in kidney transplant recipients. Rituximab is widely used in kidney transplantation for a variety of situations, and rituximab may inhibit some cytokines and antibodies that may play an active role in the atherosclerotic process. The aim of the study was to evaluate the efficacy of rituximab on atherosclerosis biomarkers in kidney transplant recipients.MethodsAll patients, 18 years of age and older, who underwent kidney transplantation and received at least 1 dose of 375 mg/m2 rituximab were considered for participation in this study. The primary study endpoint was the development of cardiovascular diseases after rituximab therapy. The secondary endpoint was the onset of cytomegalovirus (CMV) disease or biopsy-confirmed BK virus nephropathy. In addition, comparison of atherosclerosis biomarkers was performed between study and control groups.ResultsThere were no cardiovascular events observed during follow up. Only 8 patients in the study group suffered from CMV disease during follow up. Serum interleukin 10 levels were significantly higher in the rituximab group compared with the control group, although anti–oxidized low-density lipoprotein levels were lower in the rituximab group compared with the control group, though this did not achieve statistical significance.DiscussionRituximab treatment may increase the risk of CMV reactivation and decrease lymphocyte counts and interleukin 10 levels; however, significant decreases in all atherosclerotic-related biomarkers have not been shown in our study. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
